Open AccessGemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer
Author(s) -
Changhong Yu,
Hequn Chen,
Jinbo Chen,
Feng Zeng,
Xiongbing Zu,
Ding Jian
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.188434
Subject(s) - medicine , gemcitabine , neutropenia , mucositis , oncology , bladder cancer , febrile neutropenia , vinblastine , chemotherapy , cisplatin , cancer
The objective of this study was to perform a systematic review and meta-analysis to evaluate the two most commonly used chemotherapy regimens gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin/adriamycin, and cisplatin (MVAC) regimens for muscle-invasive bladder cancer (MIBC) patients.